Molecular Devices Announces the Introduction of the IMAP(TM) Progressive Binding System and Nine New Substrates

Molecular Devices Announces the Introduction of the IMAP(TM) Progressive Binding
System and Nine New Substrates 


SUNNYVALE, Calif., Nov. 6  /PRNewswire-FirstCall/ -- Molecular Devices
Corporation , a leader in innovative solutions for drug discovery and life
sciences research, today announced the launch of the most recent additions to
its IMAP(TM) platform, the IMAP Progressive Binding System and nine new peptide
substrates. With the IMAP Progressive Binding System, researchers can achieve
enhanced performance for virtually all kinases, phosphatases and
phosphodiesterases by addressing key parameters, such as substrate limitations,
ATP concentrations and background levels. The nine new peptides added to
Molecular Devices' growing line of validated peptides further support IMAP as a
complete systems approach for assaying enzyme activity.

Molecular Devices' IMAP technology is rapidly becoming the established assay
format to screen for kinase and phosphatase activity because it does not rely on
radioactivity or antibodies.  The new binding system and growing list of
validated substrates further enable the end user to develop assays for uncommon
or proprietary enzymes with the same ease of miniaturization and low
cost-per-well that IMAP users have come to expect.

"Kinases and phosphatases are screened at all major pharmaceutical companies,
and we believe that IMAP is becoming the preferred screening platform. 
Molecular Devices will continue to add key components that provide our customers
with the flexibility required to address this important yet diverse class of
drug targets," stated Stephen Oldfield, Ph.D. and Vice President of Worldwide
Marketing at Molecular Devices.  "By exploiting the ratiometric format inherent
in fluorescence polarization, IMAP leverages Molecular Devices' line of
Analyst(R) instruments which are known for setting industry standards in FP
detection."

Molecular Devices Corporation is a leading supplier of high-performance
bioanalytical measurement systems that accelerate and improve drug discovery and
other life sciences research.  The Company's systems and consumables enable
pharmaceutical and biotechnology companies to leverage advances in genomics,
proteomics and combinatorial chemistry by facilitating the high- throughput and
cost-effective identification and evaluation of drug candidates.  The Company's
solutions are based on its advanced core technologies that integrate its
expertise in engineering, molecular and cell biology and chemistry.  Molecular
Devices enables its customers to improve research productivity and
effectiveness, which ultimately accelerates the complex process of discovering
and developing new drugs.

This press release contains "forward-looking" statements, including statements
related to the prospects for the IMAP Progressive Binding System and peptide
substrates. Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects," "will," and similar
expressions are intended to identify forward-looking statements. There are a
number of important factors that could cause the results of Molecular Devices
Corporation to differ materially from those indicated by these forward-looking
statements, including, among others, risks detailed from time to time in the
Company's SEC reports, including its Annual Report on Form 10-K for the year
ended December 31, 2002 and its quarterly report on Form 10-Q for the quarter
ended September 30, 2003.  Molecular Devices Corporation does not undertake any
obligation to update forward- looking statements. 

DATASOURCE: Molecular Devices Corporation



CONTACT:  Tim Harkness of Molecular Devices Corporation, [phone]



Web site:  http://www.moleculardevices.com/ 

Copyright